Impact of pre‐existing type 2 diabetes with and without cardiovascular disease on patients with COVID ‐19
Authors' conclusion
Our study highlights the incrementally poorer outcomes associated with pre-existing T2D + CVD in COVID-19 patients compared with those without T2D/CVD and suggests consideration of a more optimal management approach in these patients.
Study context
- Population
- Patients with COVID-19 identified 3 January 2020 to 31 May 2021, HealthCore Integrated Research Database (claims, laboratory and mortality data)6,967 per group after matching
- Participants
- 321,232 patients
- Exposure
- T2D + cardiovascular disease (CVD) vs T2D only vs neither
- T2D + CVDn = 21,651
- T2D onlyn = 28,184
- Neithern = 271,397reference
- Outcome
- Hospitalization, ICU admission and mortality (adjusted analyses)
- Follow-up
- Mean (SD) 5.4 (3.0) months
Methodological detailspropensity score matching, multivariable analyses
- Propensity score matching
- Multivariable analyses
Main finding
As reported in the abstract
- T2D + CVD vs neither: more probable to be hospitalized
- 59%
- T2D + CVD vs neither: more probable to be admitted to the intensive care unit (ICU)
- 74%
- T2D + CVD vs neither: higher mortality risk
- 26%
- T2D only vs neither: more probable to be admitted to the hospital
- 28%
- T2D only vs neither: more probable to be admitted to the ICU
- 32%
Observational data: associations, not effects.
Further findings
Complications among all T2D + CVD patients
- Acute respiratory distress syndrome
- 31%
- Acute kidney disease
- 24%
Original publication
Impact of pre‐existing type 2 diabetes with and without cardiovascular disease on patients with COVID ‐19. Diabetes Obes Metab. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →